Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 31;109(2):djw248.
doi: 10.1093/jnci/djw248. Print 2017 Feb.

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

Carla Casulo  1 , Owen O'Connor  2 , Andrei Shustov  3 , Michelle Fanale  4 , Jonathan W Friedberg  1 , John P Leonard  5 , Brad S Kahl  6 , Richard F Little  7 , Lauren Pinter-Brown  8 , Ranjani Advani  9 , Steven Horwitz  10
Affiliations
Review

T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment

Carla Casulo et al. J Natl Cancer Inst. .

Abstract

Peripheral T-cell lymphomas (PTCLs) are uncommon, heterogeneous, and aggressive non-Hodgkin's lymphomas. Despite progress in the last several years resulting in a deeper understanding of PTCL biology and pathogenesis, there is currently no accepted single standard of care for newly diagnosed patients, and for those with relapsed or refractory disease, prognosis is dismal. The National Cancer Institute convened a Clinical Trials Planning Meeting to advance the national clinical trial agenda in lymphoma. The objective was to identify unmet needs specific to five major lymphoma subtypes and develop strategies to address them. This consensus statement reviews recent advances in the molecular and genetic characterization of PTCL that may inform novel treatments, proposes strategies to test novel therapies in the relapsed setting with the hopes of rapid advancement into frontline trials, and underscores the need for the identification and development of active and biologically rational therapies to cure PTCL at higher rates, with iterative biomarker evaluation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
In the relapsed setting, outcomes for peripheral T-cell lymphoma (PTCL) are dismal. Noted here is a representative example from a recently completed Southwest Oncology Group trial evaluating alisertib in relapsed/refractory PTCL (33). This figure is being published with permission from the original authors and copyright holder.
Figure 2.
Figure 2.
Proposed strategy for developing the next generation of clinical trials in T-cell lymphoma (TCL). A) Relapsed disease with representative examples. B) Frontline setting with representative examples. C) Clinical trials in TCL that include a putative biomarker (as an example, CD30). TCL = T-cell lymphoma.
See this image and copyright information in PMC

References

    1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997;89(11):3909–3918. - PubMed
    1. Swerdlow SHN, Jaffe E, Pileri S, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed Lyon, France: International Agency for Research on Cancer; 2008.
    1. Ellin F, Landstrom J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the Swedish Lymphoma Registry. Blood. 2014;124(10):1570–1577. - PubMed
    1. Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130. - PubMed
    1. Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. J Clin Oncol. 2009;27(1):106–113. - PubMed

Publication types

MeSH terms